Abstract: In recent years, a number of large randomized controlled trials have demonstrated the cardio-renal protective effect of sodium glucose co-transporter-2 inhibitors (SGLT2i). A newly published collaborative meta-analysis assessed the effects of SGLT2i on kidney progression, acute kidney injury and other key outcomes in patients with or without diabetes, by incorporating data from all available trials and standardizing outcome definitions, and thus provided high-quality evidence to guide clinical practice for the use of these drugs.

Key words: sodium glucose co-transporter-2 inhibitors, randomized controlled trial, diabetes, kidney disease